Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines

Compounds comprising:

• 1) A first compound according to formula (I)
• wherein
• L is selected from the group consisting of NH, CH2, S and O;
• R1 is selected from the group consisting of hydrogen, linear or branched C1-C5 alkyl, C1-C5 fluoroalkyl and saturated monocyclic C3-C5 cycloalkyl;
• R2 is selected from the group consisting of linear or branched C1-C8 alkyl, saturated monocyclic C3-C8 cycloalkyl, oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl;
• all of which can be optionally substituted one or more times with one or more substituents selected from the group consisting of methyl, fluorine, hydroxy, cyano and methoxy;
• R3 is methyl substituted with phenyl, pyridonyl, pyridinyl, pyrimidinyl or pyrazinyl all of which can be optionally substituted one or more times with one or more substituents selected from the group consisting of halogen, cyano, C1-C3 alkyl, C1-C3 fluoroalkyl, C1-C3 fluoroalkoxy and C1-C3 alkoxy;
• or
• R3 is methyl substituted with a 5-membered heteroaryl which is optionally substituted with one or more substituents selected from halogen, cyano, C1-C3 alkyl, C1-C3 fluoroalkyl, C1-C3 fluoroalkoxy and C1-C3 alkoxy;
• or
• R3 is ethyl substituted with phenyl, pyridonyl, pyridinyl, pyrimidinyl or pyrazinyl all of which can be optionally substituted one or more times with one or more substituents selected from the group consisting of halogen, cyano, C1-C3 alkyl, C1-C3 fluoroalkyl, C1-C3 fluoroalkoxy and C1-C3 alkoxy;
• or
• R3 is ethyl substituted with a 5-membered heteroaryl which is optionally substituted with one or more substituents selected from halogen, cyano, C1-C3 alkyl, C1-C3 fluoroalkyl, C1-C3 fluoroalkoxy and C1-C3 alkoxy;
• or
• L is CH2 and R3 is NH which is substituted with phenyl, pyridonyl, pyridinyl, pyrimidinyl or pyrazinyl all of which can be optionally substituted one or more times with one or more substituents selected from the group consisting of halogen, cyano, C1-C3 alkyl, C1-C3 fluoroalkyl, C1-C3 fluoroalkoxy and C1-C3 alkoxy;
• or
• L is CH2 and R3 is NH which is substituted with a 5-membered heteroaryl which is optionally substituted with one or more substituents selected from halogen, cyano, C1-C3 alkyl, C1-C3 fluoroalkyl, C1-C3 fluoroalkoxy and C1-C3 alkoxy;
• R4 is phenyl, pyridinyl or pyridonyl all of which can be optionally substituted one or more times with one or more substituents selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 deutereoalkyl, C1-C3 fluoroalkoxy, cyclopropyloxy, C1-C3 alkoxy, C1-C3 deutereoalkoxy and —N-R5R6 wherein R5 and R6 are each independently selected from H, C1-C3 alkyl and C1-C3 deutereoalkyl;
• or
• R4 is a 5-membered heteroaryl which is optionally substituted with one or more substituents selected from halogen, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 deutereoalkyl, C1-C3 fluoroalkoxy, cyclopropyloxy, C1-C3 alkoxy, C1-C3 deutereoalkoxy and —N-R5R6 wherein R5 and R6 are each independently selected from H, C1-C3 alkyl and C1-C3 deutereoalkyl;
• or
• R4 is a 4, 5 or 6 membered saturated heterocycle all of which can be optionally substituted with one or more substituents selected from oxo, C1-C4 alkyl and C1-C4 fluoroalkyl;
• or a pharmaceutically acceptable salt thereof, and
• 2) A second compound, which compound is useful in the treatment of a psychiatric disorder, wherein 1) and 2) are for combined use in the treatment of a psychiatric and/or cognitive disorder, wherein said psychiatric and/or cognitive disorder is selected from the list consisting of Attention Deficit hyperactivity Disorder (ADHD), depression, anxiety, narcolepsy, cognitive impairment, schizophrenia, cognitive impairment associated with schizophrenia (CIAS), and restless leg syndrome.